Neurogene PEG

Mitä Neurogene tekee? Neurogene Inc develops genetic medicines for rare neurological diseases using its EXACT transgene regulation platform technology. The company focuses on creating treatments like NGN-401, an AAV9 gene therapy candidate for Rett syndrome, and NGN-101 for CLN5 Batten disease. These products target patients with devastating neurological conditions, aiming to overcome limitations of conventional gene therapy by delivering therapeutic levels while minimizing transgene toxicity. The firm advances multiple discovery-stage candidates through its proprietary technology. The company's revenue model relies on developing and advancing its product candidates through clinical stages, with NGN-401 and NGN-101 being the primary focus. Neurogene Inc. is a biotechnology firm that operates in the US, targeting patients affected by rare neurological diseases through its innovative gene therapy approaches. The company's products are designed to address unmet medical needs in central nervous system disorders, leveraging its EXACT platform to optimize therapeutic outcomes. Neurogene Inc. was formerly known as Neoleukin Therapeutics, Inc., and its business strategy centers on developing novel gene therapies for rare conditions. The company's EXACT technology enables precise transgene regulation, which is critical for treating neurological diseases where conventional gene therapy has shown limitations. By focusing on Rett syndrome and CLN5 Batten disease, Neurogene Inc. targets specific patient segments with high unmet medical needs, aiming to provide safer and more effective treatment options. Neurogene on yksi Eurpooliin suosituimmista yhtiöistä.